Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

2.

Acute Onset of Guillain-Barré Syndrome After Elective Spinal Surgery.

Boghani Z, Livingston AD, Simpson EP, Holman PJ, Grossman RG.

World Neurosurg. 2015 Aug;84(2):376-9. doi: 10.1016/j.wneu.2015.03.036. Epub 2015 Mar 30.

PMID:
25836269
3.

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M; MDA Clinical Research Network.

Lancet. 2014 Jun 14;383(9934):2065-72. doi: 10.1016/S0140-6736(14)60222-1. Epub 2014 Feb 28.

4.

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group.

Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3.

5.

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.

Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA.

Neurology. 2008 Nov 25;71(22):1770-5. doi: 10.1212/01.wnl.0000335970.78664.36.

6.

Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis.

Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U.

Neurology. 2008 Oct 21;71(17):1326-34. doi: 10.1212/01.wnl.0000327668.43541.22.

PMID:
18936424
7.

Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery.

Gwinn K, Corriveau RA, Mitsumoto H, Bednarz K, Brown RH Jr, Cudkowicz M, Gordon PH, Hardy J, Kasarskis EJ, Kaufmann P, Miller R, Sorenson E, Tandan R, Traynor BJ, Nash J, Sherman A, Mailman MD, Ostell J, Bruijn L, Cwik V, Rich SS, Singleton A, Refolo L, Andrews J, Zhang R, Conwit R, Keller MA; ALS Research Group.

PLoS One. 2007 Dec 5;2(12):e1254.

8.

Whole-genome analysis of sporadic amyotrophic lateral sclerosis.

Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O'connor DT, Zhang K, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH, Stephan DA.

N Engl J Med. 2007 Aug 23;357(8):775-88. Epub 2007 Aug 1.

9.

The value of database controls in pilot or futility studies in ALS.

Czaplinski A, Haverkamp LJ, Yen AA, Simpson EP, Lai EC, Appel SH.

Neurology. 2006 Nov 28;67(10):1827-32.

PMID:
17130417
10.

Predictability of disease progression in amyotrophic lateral sclerosis.

Czaplinski A, Yen AA, Simpson EP, Appel SH.

Muscle Nerve. 2006 Dec;34(6):702-8.

PMID:
16967489
13.

Antioxidant treatment for amyotrophic lateral sclerosis.

Simpson EP.

Lancet Neurol. 2005 May;4(5):266. Review. No abstract available.

PMID:
15847835
14.

Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism.

Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH.

J Neuropathol Exp Neurol. 2004 Sep;63(9):964-77.

PMID:
15453095
15.

Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden.

Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH.

Neurology. 2004 May 25;62(10):1758-65.

PMID:
15159474
16.

HFE mutations are not strongly associated with sporadic ALS.

Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH.

Neurology. 2004 May 11;62(9):1611-2.

PMID:
15136693
17.

Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue.

Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH.

Ann Neurol. 2004 Feb;55(2):221-35.

PMID:
14755726
18.

Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis.

Simpson EP, Yen AA, Appel SH.

Curr Opin Rheumatol. 2003 Nov;15(6):730-6. Review.

PMID:
14569202
19.

PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients.

Kim SH, Henkel JS, Beers DR, Sengun IS, Simpson EP, Goodman JC, Engelhardt JI, Siklós L, Appel SH.

J Neuropathol Exp Neurol. 2003 Jan;62(1):88-103.

PMID:
12528821
20.

Mechanisms of disease pathogenesis in amyotrophic lateral sclerosis. A central role for calcium.

Simpson EP, Mosier D, Appel SH.

Adv Neurol. 2002;88:1-19. Review. No abstract available.

PMID:
11908220

Supplemental Content

Loading ...
Support Center